Stocks · News reference
BioMarin Pharmaceutical shares are trading higher after Canaccord Genuity maintained its Buy rating on the stock and raised its price target from $111 to $114.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 5:47 PM
- Checked
- Aug 10, 2026, 5:47 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Why Is BitMine Immersion Stock Surging on Thursday?
Shares of Bitmine Immersion Technologies Inc (NYSE: BMNR) are rising Thursday on Ethereum treasury growth and updates from Tom Lee.
Read original at benzingaBitcoin, XRP, Dogecoin Dip; Ethereum Rises Amid Hot Inflation Print: Correction Aside, Bitcoin's Structure 'Intact,' Says Popular Analyst
Leading cryptocurrencies stalled on Wednesday, August 26, after the Federal Reserve's preferred inflation gauge came in higher than expected.
Read original at benzingaBitcoin, Ethereum, XRP, Dogecoin Retreat Even as 'Greed' Sentiment Prevails: Analyst Charts Two Possible Scenarios for BTC
Leading cryptocurrencies pulled back on Tuesday, August 25, as investors locked in profits from the recent rally.
Read original at benzinga